Literature DB >> 18579189

Lymphovascular invasion and pathologic tumor stage are significant outcome predictors for patients with upper tract urothelial carcinoma.

Christian Bolenz1, Mario I Fernández, Lutz Trojan, Edwin Herrmann, Andreas Becker, Christel Weiss, Peter Alken, Philipp Ströbel, Maurice Stephan Michel.   

Abstract

OBJECTIVES: To determine the predictors of urothelial recurrence, distant metastases, and disease-specific survival (DSS) after radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC).
METHODS: The records of 136 patients who underwent RNU in our department between 1983 and 2004 were reviewed. The study population consisted of 116 patients from whom tumor specimens were available for re-evaluation, focusing on pathologic tumor (pT) stage, grade, lymphovascular invasion (LVI), concomitant carcinoma in situ (CIS), and the presence of significant tumor necrosis. Univariate and multivariate analyses were performed.
RESULTS: The median follow-up was 38 months (range: 1-193 months). At actual follow-up, 63 patients (56%) were alive and disease-free. Concomitant CIS independently predicted urothelial recurrence (P = .008). Five-year actual DSS by pT stage was 100% for pTa and pTis, 95% for pT1, 70% for pT2, 54% for pT3, and 14% for pT4 tumors. Disease-specific mortality occurred in 32 patients (28%). A sessile tumor architecture, pT stage, grade, the presence of LVI (all P < .001), a positive surgical margin (P = .012), tumor necrosis (P = .004), and lymph node metastases (P = .034) were significantly associated with reduced DSS on univariate analysis. Multivariate analysis revealed the presence of LVI (P < .001) and pT stage (P = .023) as independent predictors for reduced DSS.
CONCLUSIONS: RNU provides adequate local control and long-term DSS in patients with localized UTUC. LVI and pT stage are independent predictors for reduced DSS and can be used for the identification of patients who are likely to benefit from adjuvant therapies.

Entities:  

Mesh:

Year:  2008        PMID: 18579189     DOI: 10.1016/j.urology.2008.04.032

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  6 in total

1.  Canadian guidelines for postoperative surveillance of upper urinary tract urothelial carcinoma.

Authors:  Anil Kapoor; Christopher B Allard; Peter Black; Wassim Kassouf; Christopher Morash; Ricardo Rendon
Journal:  Can Urol Assoc J       Date:  2013 Sep-Oct       Impact factor: 1.862

2.  Upper urinary tract urothelial carcinoma: what have we learned in the last 4 years?

Authors:  Mesut Remzi; Shahrokh Shariat; Wilhelm Huebner; Harun Fajkovic; Christian Seitz
Journal:  Ther Adv Urol       Date:  2011-04

3.  The result of adjuvant chemotherapy for localized pT3 upper urinary tract carcinoma in a multi-institutional study.

Authors:  Atsunari Kawashima; Yasutomo Nakai; Masashi Nakayama; Takeshi Ujike; Go Tanigawa; Yutaka Ono; Akihito Kamoto; Tsuyosi Takada; Yuichiro Yamaguchi; Hitoshi Takayama; Kazuo Nishimura; Norio Nonomura; Akira Tsujimura
Journal:  World J Urol       Date:  2011-10-09       Impact factor: 4.226

4.  Can lymphovascular invasion replace the prognostic value of lymph node involvement in patients with upper tract urothelial carcinoma after radical nephroureterectomy?

Authors:  Eun Sang Yoo; Yun-Sok Ha; Jun Nyung Lee; Bum Soo Kim; Bup Wan Kim; Seok-Soo Byun; Young Deuk Choi; Ho Won Kang; Seok-Joong Yun; Wun-Jae Kim; Jeong Hyun Kim; Tae Gyun Kwon
Journal:  Can Urol Assoc J       Date:  2016-07-12       Impact factor: 1.862

Review 5.  Perioperative chemotherapy for upper tract urothelial cancer.

Authors:  Ajjai S Alva; Surena F Matin; Seth P Lerner; Arlene O Siefker-Radtke
Journal:  Nat Rev Urol       Date:  2012-04-10       Impact factor: 14.432

6.  Competing-risks nomogram for predicting cancer-specific death in upper tract urothelial carcinoma: a population-based analysis.

Authors:  Chengzhuo Li; Didi Han; Qiao Huang; Fengshuo Xu; Shuai Zheng; Xiang Li; Fanfan Zhao; Xiaojie Feng; Jun Lyu
Journal:  BMJ Open       Date:  2021-07-19       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.